Palonosetron Anfarm

Palonosetron, the active ingredient in Palonosetron Anfarm, is a 5‑HT3 receptor antagonist presented as a unknown/unknown for injection use. It treats and prevents chemotherapy‑induced nausea and vomiting in adult cancer patients. GNH USA supplies Palonosetron Anfarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Palonosetron Anfarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Palonosetron is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting related to chemotherapy and surgery.

- Chemotherapy‑induced nausea and vomiting (CINV): Reduces the frequency and severity of acute and delayed episodes. - Post‑operative nausea and vomiting (PONV): Decreases the incidence of nausea after surgical procedures. - Radiotherapy‑induced nausea and vomiting: Helps mitigate the nausea associated with radiation treatment. - Antiemetic prophylaxis in high‑risk patients: Provides preventative control for patients identified as high‑risk for severe nausea and vomiting. - Adjunct to other antiemetics: Enhances the overall anti‑emetic regimen when combined with drugs of different mechanisms. - C ​  

Palonosetron   

Common  

-   …  ... ...  t    ... ... ... ... ... ... ... ... ...

Palonoset‑